Trial · NCT02682784
Neural Substrates of Emotion: Impact of Cocaine Dependence
NCT02682784, Phase 2, Completed, Medical University of South Carolina; results first posted 2021-10-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neural Substrates of Emotion: Impact of Cocaine Dependence. Trials, record NCT02682784. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02682784
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neural Substrates of Emotion: Impact of Cocaine Dependence
- NCT number
- NCT02682784
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 138 participants, actual
- Lead sponsor
- Medical University of South Carolina
- Conditions
- Cocaine Use Disorder
- Interventions
- Oxytocin, Placebo
- First posted
- 2016-02-15
- Last updated
- 2021-10-21
- Results first posted
- 2021-10-21
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress | During Montreal Imaging Stress Task in fMRI scanner | Psychophysiological interaction (PPI) analysis measures how strongly one region of the brain is connected to another brain region during a particular experimental condition, such as doing arithmetic while being given feedback about performance. The strength of this functional connection between two regions can be expressed as a parameter estimate - the higher the value of the parameter estimate, the more strongly connected the two regions are so that as activation in one region increases, activation in the connected region also increases. However, two regions can also be strongly negatively connected such that if activation in one region goes up during a task condition, activation in the other region goes down |
| Primary | Amygdala Activity in Response to Fearful Faces | During Facial Recognition Task in fMRI scanner | Use an implicit facial affect recognition paradigm to determine the impact of cocaine dependence and oxytocin on amygdala activity in response to fearful faces. The BOLD signal measured during neutral faces will be subtracted from the BOLD signal measured during fearful faces. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress | During Montreal Imaging Stress Task in fMRI scanner | Some scans were not useable to due to head movement. | Arbitrary units | MEAN |
| PRIMARY | Amygdala Activity in Response to Fearful Faces | During Facial Recognition Task in fMRI scanner | Some scans were not useable due to head movement. | Bold signal | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress | Oxytocin/Cocaine User | .011 | Standard Deviation .099 | Arbitrary units | |
| Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress | Placebo/Cocaine User | .012 | Standard Deviation .103 | Arbitrary units | |
| Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress | Oxytocin/Control | .043 | Standard Deviation .097 | Arbitrary units | |
| Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress | Placebo/Control | .0008 | Standard Deviation .149 | Arbitrary units | |
| Amygdala Activity in Response to Fearful Faces | Oxytocin/Cocaine User | 8.33 | Standard Deviation 48.9 | Bold signal | |
| Amygdala Activity in Response to Fearful Faces | Placebo/Cocaine User | 2.32 | Standard Deviation 47.6 | Bold signal | |
| Amygdala Activity in Response to Fearful Faces | Oxytocin/Control | 11.98 | Standard Deviation 30.4 | Bold signal | |
| Amygdala Activity in Response to Fearful Faces | Placebo/Control | 18.07 | Standard Deviation 30.8 | Bold signal |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Oxytocin/Cocaine User | 40 | |
| Overall Study | STARTED | Placebo/Cocaine User | 37 | |
| Overall Study | STARTED | Oxytocin/Control | 29 | |
| Overall Study | STARTED | Placebo/Control | 32 | |
| Overall Study | COMPLETED | Oxytocin/Cocaine User | 39 | |
| Overall Study | COMPLETED | Placebo/Cocaine User | 35 | |
| Overall Study | COMPLETED | Oxytocin/Control | 27 | |
| Overall Study | COMPLETED | Placebo/Control | 29 | |
| Overall Study | NOT COMPLETED | Oxytocin/Cocaine User | 1 | |
| Overall Study | NOT COMPLETED | Placebo/Cocaine User | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Oxytocin/Cocaine User | 0 | 39 |
| Total, all-cause mortality | Placebo/Cocaine User | 0 | 35 |
| Total, all-cause mortality | Oxytocin/Control | 0 | 27 |
| Total, all-cause mortality | Placebo/Control | 0 | 29 |
| Total, other adverse events | Oxytocin/Cocaine User | 0 | 39 |
| Total, other adverse events | Placebo/Cocaine User | 0 | 35 |
| Total, other adverse events | Oxytocin/Control | 0 | 27 |
| Total, other adverse events | Placebo/Control | 0 | 29 |
| Total, serious adverse events | Oxytocin/Cocaine User | 0 | 39 |
| Total, serious adverse events | Placebo/Cocaine User | 0 | 35 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Emoji Emotion Recognition | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02682784
GET https://conductscience.org/api/trials/v1/NCT02682784/registered